

<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.23.6 -->
<!-- Round: 3 -->
<!-- Creation date: 2016-08-06T07:35:57Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:galt="http://www.galectintherapeutics.com/20160630" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="galt-20160630.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <galt:FairValueOfAssetContributedToJointVenture contextRef="eol_PE87402---1610-Q0007_STD_0_20140131_0_1324491x1345331_1328480x1513856_1331352x1334714" unitRef="iso4217_USD" decimals="0" id="id_8252787_875CF1B6-F1CC-45AC-80E3-7DA46B538A83_2002_1">400000</galt:FairValueOfAssetContributedToJointVenture>
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="eol_PE87402---1610-Q0007_STD_0_20140131_0_1328480x1513856" unitRef="pure" decimals="INF" id="id_8252787_875CF1B6-F1CC-45AC-80E3-7DA46B538A83_3002_3">0.500</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE87402---1610-Q0007_STD_0_20160805_0" unitRef="shares" decimals="INF" id="id_8252787_C4C4CF4A-0BEB-4BD7-97AB-2AED8E28F92C_2_500005">29280653</dei:EntityCommonStockSharesOutstanding>
  <galt:AggregateOfferingPrice contextRef="eol_PE87402---1610-Q0007_STD_0_20140330_0_1327036x1459062" unitRef="iso4217_USD" decimals="-5" id="id_8252787_9CDF1BA3-D5D2-47DA-96F0-982D0C0C4ABE_1001_0">30000000</galt:AggregateOfferingPrice>
  <galt:CommissionsAsPercentageOfGrossOfferingProceeds contextRef="eol_PE87402---1610-Q0007_STD_0_20140330_0_1327036x1459062" unitRef="pure" decimals="3" id="id_8252787_9CDF1BA3-D5D2-47DA-96F0-982D0C0C4ABE_1001_1">0.030</galt:CommissionsAsPercentageOfGrossOfferingProceeds>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="eol_PE87402---1610-Q0007_STD_0_20150312_0_1324199x1332392_1330194x1394132" unitRef="iso4217_USD" decimals="INF" id="id_8252787_E08F6591-16D8-477E-A4EE-C130B517EA8E_4001_3">280000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNonEmployeeDirectorsGrantedShares contextRef="eol_PE87402---1610-Q0007_STD_0_20150312_0_1324199x1332392_1330194x1394132" unitRef="Director" decimals="INF" id="id_8252787_E08F6591-16D8-477E-A4EE-C130B517EA8E_4001_2">7</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNonEmployeeDirectorsGrantedShares>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="eol_PE87402---1610-Q0007_STD_0_20150312_0_1324199x1332392_1330194x1472563" unitRef="iso4217_USD" decimals="INF" id="id_8252787_E08F6591-16D8-477E-A4EE-C130B517EA8E_5001_7">12845</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNonEmployeeDirectorsGrantedShares contextRef="eol_PE87402---1610-Q0007_STD_0_20150312_0_1324199x1332392_1330194x1472563" unitRef="Director" decimals="INF" id="id_8252787_E08F6591-16D8-477E-A4EE-C130B517EA8E_5001_6">2</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNonEmployeeDirectorsGrantedShares>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE87402---1610-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_1002_16">26362000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_41">1377500</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_45">50000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_47">29280653</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="shares" decimals="INF" id="id_8252787_0CFF23DA-4B51-4833-99A7-C14D3967F2DB_2001_1">588929</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_44">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_46">29280653</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_40">1377500</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="shares" decimals="INF" id="id_8252787_7A8CAF4E-98AB-4CC0-919B-A665DF95C604_3001_6">3499638</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8252787_02A8D56D-ECA6-4B2B-9D5A-3A3466F94C00_3001_6">5.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_39">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_49">-152887000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PreferredStockValue contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_38">557000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="0" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_42">1377500</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:Liabilities contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_13">3636000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_51">18247000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F23BA1BE-2674-45E3-A092-ED3C5261579C_1001_1">493000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_9">932000</us-gaap:AccountsPayableCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_50">7487000</us-gaap:StockholdersEquity>
  <us-gaap:DividendsPayableCurrent contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_11">68000</us-gaap:DividendsPayableCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_43">29000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_48">159788000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F23BA1BE-2674-45E3-A092-ED3C5261579C_1001_0">191000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_14" />
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_12">3636000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_10">2636000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_4">18242000</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_2">18003000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="0" id="id_8252787_0CFF23DA-4B51-4833-99A7-C14D3967F2DB_2001_0">1235000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_5">5000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:Assets contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_6">18247000</us-gaap:Assets>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_3">239000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <galt:UndesignatedCapitalStockSharesAuthorized contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_36">20000000</galt:UndesignatedCapitalStockSharesAuthorized>
  <galt:UndesignatedCapitalStockSharesOutstanding contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_37">8001000</galt:UndesignatedCapitalStockSharesOutstanding>
  <galt:UndesignatedCapitalStockParValue contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_35">0.01</galt:UndesignatedCapitalStockParValue>
  <galt:UndesignatedCapitalStockValue contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1_34">0</galt:UndesignatedCapitalStockValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1324199x1332392" unitRef="shares" decimals="INF" id="id_8252787_D83D432F-D538-4C61-A63E-13EB8C681DAF_4001_5">754605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1328480x1513856" unitRef="pure" decimals="3" id="id_8252787_875CF1B6-F1CC-45AC-80E3-7DA46B538A83_3005_3">0.802</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1329983" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1001_30">176</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1329983" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1001_29">176</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1329983" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1001_28">1000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:RedeemableNoncontrollingInterestEquityPreferredRedemptionValue contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1329983" unitRef="iso4217_USD" decimals="0" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1001_31">6434000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredRedemptionValue>
  <us-gaap:TemporaryEquityLiquidationPreference contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1329983" unitRef="iso4217_USD" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1001_32">1760000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1329983" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1001_27">1723000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1439796" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2001_24">2100000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1439796" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2001_23">2100000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1439796" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2001_22">2100000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:RedeemableNoncontrollingInterestEquityPreferredRedemptionValue contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1439796" unitRef="iso4217_USD" decimals="0" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2001_25">4200000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredRedemptionValue>
  <us-gaap:TemporaryEquityLiquidationPreference contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1439796" unitRef="iso4217_USD" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2001_26">4200000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1439796" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2001_21">3645000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1466234" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_3001_18">900000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1466234" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_3001_17">900000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1466234" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_3001_16">900000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:RedeemableNoncontrollingInterestEquityPreferredRedemptionValue contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1466234" unitRef="iso4217_USD" decimals="0" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_3001_19">1800000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredRedemptionValue>
  <us-gaap:TemporaryEquityLiquidationPreference contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1466234" unitRef="iso4217_USD" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_3001_20">1800000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1466234" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_3001_15">1756000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330097x1336129" unitRef="shares" decimals="INF" id="id_8252787_FF57A2D7-6966-499B-9323-10F2338CEBE6_4001_6">8908586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330097x1336129" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8252787_D4E04A5F-AFE3-4BFF-B2D1-E204048F825F_4001_6">3.18</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="eol_PE87402---1610-Q0007_STD_0_20160630_0_1336123x1454011" unitRef="shares" decimals="INF" id="id_8252787_0CFF23DA-4B51-4833-99A7-C14D3967F2DB_3001_6">208125</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE87402---1610-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_2001_15">29128000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_41">1377500</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_45">50000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_47">28825033</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_44">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_46">28825033</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_40">1377500</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_8252787_7A8CAF4E-98AB-4CC0-919B-A665DF95C604_1001_2">3342325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8252787_02A8D56D-ECA6-4B2B-9D5A-3A3466F94C00_1001_2">5.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_39">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_49">-140049000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PreferredStockValue contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_38">557000</us-gaap:PreferredStockValue>
  <us-gaap:Liabilities contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_13">1360000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_51">26408000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F23BA1BE-2674-45E3-A092-ED3C5261579C_1002_1">626000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_9">448000</us-gaap:AccountsPayableCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_50">18040000</us-gaap:StockholdersEquity>
  <us-gaap:DividendsPayableCurrent contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_11">67000</us-gaap:DividendsPayableCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_43">28000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_48">157504000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F23BA1BE-2674-45E3-A092-ED3C5261579C_1002_0">123000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_14" />
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_12">1360000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_10">845000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_4">26400000</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_2">25846000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_5">8000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:Assets contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_6">26408000</us-gaap:Assets>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_3">554000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <galt:UndesignatedCapitalStockSharesAuthorized contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_36">20000000</galt:UndesignatedCapitalStockSharesAuthorized>
  <galt:UndesignatedCapitalStockSharesOutstanding contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_37">8001000</galt:UndesignatedCapitalStockSharesOutstanding>
  <galt:UndesignatedCapitalStockParValue contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_35">0.01</galt:UndesignatedCapitalStockParValue>
  <galt:UndesignatedCapitalStockValue contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2_34">0</galt:UndesignatedCapitalStockValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0_1324199x1332392" unitRef="shares" decimals="INF" id="id_8252787_D83D432F-D538-4C61-A63E-13EB8C681DAF_1001_1">754605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0_1328480x1513856" unitRef="pure" decimals="3" id="id_8252787_875CF1B6-F1CC-45AC-80E3-7DA46B538A83_3001_3">0.747</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0_1330096x1329983" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1002_30">176</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0_1330096x1329983" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1002_29">176</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0_1330096x1329983" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1002_28">1000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0_1330096x1329983" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_1002_27">1723000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0_1330096x1439796" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2002_24">2100000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0_1330096x1439796" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2002_23">2100000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0_1330096x1439796" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2002_22">2100000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0_1330096x1439796" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_2002_21">3537000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0_1330096x1466234" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_3002_18">900000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0_1330096x1466234" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_3002_17">900000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0_1330096x1466234" unitRef="shares" decimals="INF" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_3002_16">900000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0_1330096x1466234" unitRef="iso4217_USD" decimals="-3" id="id_8252787_A18410D3-EF1B-4E00-9061-BADB051DD430_3002_15">1748000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0_1330097x1336129" unitRef="shares" decimals="INF" id="id_8252787_FF57A2D7-6966-499B-9323-10F2338CEBE6_1001_2">8908586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE87402---1610-Q0007_STD_0_20151231_0_1330097x1336129" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8252787_D4E04A5F-AFE3-4BFF-B2D1-E204048F825F_1001_2">3.18</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE87402---1610-Q0007_STD_1_20150312_0_1324199x1332392" unitRef="shares" decimals="INF" id="id_8252787_E08F6591-16D8-477E-A4EE-C130B517EA8E_1001_0">81352</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE87402---1610-Q0007_STD_1_20150312_0_1324199x1332392_1330194x1394132" unitRef="shares" decimals="INF" id="id_8252787_E08F6591-16D8-477E-A4EE-C130B517EA8E_2001_1">77784</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <galt:ShareBasedCompensationCostRecognitionDateLatest contextRef="eol_PE87402---1610-Q0007_STD_1_20150312_0_1324199x1332392_1330194x1394132" id="id_8252787_E08F6591-16D8-477E-A4EE-C130B517EA8E_2001_4">2016-12-15</galt:ShareBasedCompensationCostRecognitionDateLatest>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE87402---1610-Q0007_STD_1_20150312_0_1324199x1332392_1330194x1472563" unitRef="shares" decimals="INF" id="id_8252787_E08F6591-16D8-477E-A4EE-C130B517EA8E_3001_5">3568</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <galt:ShareBasedCompensationCostRecognitionDateLatest contextRef="eol_PE87402---1610-Q0007_STD_1_20150312_0_1324199x1332392_1330194x1472563" id="id_8252787_E08F6591-16D8-477E-A4EE-C130B517EA8E_3001_8">2016-12-15</galt:ShareBasedCompensationCostRecognitionDateLatest>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="shares" decimals="INF" id="id_8252787_FE55DE2E-83D2-4220-BA95-CE3BBAA7B77D_2_4">11428358</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_2_8">-7298000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" id="id_8252787_37C6FA08-A4DD-418A-94C4-28C21344CD35_2_1">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="pure" decimals="2" id="id_8252787_37C6FA08-A4DD-418A-94C4-28C21344CD35_2_3">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="pure" decimals="4" id="id_8252787_37C6FA08-A4DD-418A-94C4-28C21344CD35_2_0">0.0164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="shares" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_4_13">23398000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_4_12">-0.43</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="pure" decimals="2" id="id_8252787_37C6FA08-A4DD-418A-94C4-28C21344CD35_2_2">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_4_4">-9497000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_4_8">-9469000</us-gaap:NetIncomeLoss>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_4_6">28000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_4_7">28000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_4_11">-10005000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_2_6">-228000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_2_3">4000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_2_10">0</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_4_9">421000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_2_12">4532000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_B01A1D88-4B6D-4992-8340-7893D8EB6CF7_4_2">1734000</us-gaap:ShareBasedCompensation>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_4_2">3761000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_2_13">4532000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_4_10">115000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_4_1">5736000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_2_14">-2766000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_2_7">205000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:OperatingExpenses contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_4_3">9497000</us-gaap:OperatingExpenses>
  <galt:SupplementalDividendsOnConvertiblePreferredStock contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_2_18">421000</galt:SupplementalDividendsOnConvertiblePreferredStock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0_1333589x1330141" unitRef="shares" decimals="INF" id="id_8252787_FE55DE2E-83D2-4220-BA95-CE3BBAA7B77D_1002_2">2527103</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0_1333589x1331109" unitRef="shares" decimals="INF" id="id_8252787_FE55DE2E-83D2-4220-BA95-CE3BBAA7B77D_2002_1">3192325</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0_1333589x1332392" unitRef="shares" decimals="INF" id="id_8252787_FE55DE2E-83D2-4220-BA95-CE3BBAA7B77D_3002_3">337935</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0_1333589x1336129" unitRef="shares" decimals="INF" id="id_8252787_FE55DE2E-83D2-4220-BA95-CE3BBAA7B77D_4002_0">5370995</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0_1334666x1328189" unitRef="iso4217_USD" decimals="-3" id="id_8252787_B01A1D88-4B6D-4992-8340-7893D8EB6CF7_1004_1">1191000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1610-Q0007_STD_181_20150630_0_1334666x1332399" unitRef="iso4217_USD" decimals="-3" id="id_8252787_B01A1D88-4B6D-4992-8340-7893D8EB6CF7_2004_0">543000</us-gaap:ShareBasedCompensation>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_7CC9C530-EDB4-4CEF-8377-78A8F827EC4A_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;2. Accrued Expenses&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued expenses consist of the following:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;June&amp;#xA0;30,&lt;br /&gt;
 2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;December&amp;#xA0;31,&lt;br /&gt;
 2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;(in thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Legal and accounting fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;191&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;493&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;626&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued research and development costs and other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,952&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,636&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;845&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="shares" decimals="INF" id="id_8252787_FE55DE2E-83D2-4220-BA95-CE3BBAA7B77D_1_4">15269095</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_5B3E4101-3633-4847-BD24-A0406DA0BD3A_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;8. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Shareholder Class Actions and Derivative Lawsuits&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Between July&amp;#xA0;30, 2014, and August&amp;#xA0;6, 2014, three putative
 class action complaints were filed in the United States District
 Court for the District of Nevada (the &amp;#x201C;Nevada District
 Court&amp;#x201D;) against the Company and certain of its officers and
 directors on behalf of all persons who purchased or otherwise
 acquired the Company&amp;#x2019;s stock between January&amp;#xA0;6, 2014 and
 July&amp;#xA0;28, 2014. The complaints allege that the defendants made
 false or misleading statements in certain press releases and other
 public statements in violation of the federal securities laws and
 seek class certification, unspecified monetary damages, costs, and
 attorneys&amp;#x2019; fees. The Company disputes the allegations in the
 complaints and intends to vigorously defend against the claims. On
 August&amp;#xA0;22, 2014, the Nevada District Court entered an order
 consolidating the three cases, relieving the defendants of any
 obligation to respond to the complaints then on file, and providing
 that defendants may respond to a consolidated amended complaint to
 be filed by a lead plaintiff(s) to be appointed pursuant to the
 Private Securities Litigation Reform Act of 1995. On
 January&amp;#xA0;5, 2015, the Nevada District Court granted
 Defendants&amp;#x2019; motion to transfer the consolidated putative
 securities class action to the United States District Court for the
 Northern District of Georgia. On March&amp;#xA0;24, 2015, the Court
 appointed a lead plaintiff (&amp;#x201C;Plaintiff&amp;#x2019;). Plaintiff
 filed his Consolidated Class Action Complaint (the
 &amp;#x201C;Complaint&amp;#x201D;) on May&amp;#xA0;8, 2015. The Complaint asserts
 claims on behalf of a putative class of all persons who purchased
 or otherwise acquired the Company&amp;#x2019;s common stock between
 October&amp;#xA0;25, 2013 and July&amp;#xA0;28, 2014. The Complaint alleges
 that the Company and certain of its officers and directors (the
 &amp;#x201C;Class Action Individual Defendants&amp;#x201D;) violated
 Section&amp;#xA0;10(b) of the Securities Exchange Act of 1934 (the
 &amp;#x201C;Exchange Act&amp;#x201D;) and SEC Rule 10b-5 through allegedly
 false or misleading statements in certain SEC filings, press
 releases and other public statements. The Complaint further alleges
 that the Class Action Individual Defendants and one of the
 Company&amp;#x2019;s shareholders face liability for the alleged
 Section&amp;#xA0;10(b) and Rule 10b-5 violations pursuant to
 Section&amp;#xA0;20(a) of the Exchange Act. The Complaint seeks class
 certification, unspecified monetary damages, costs, and
 attorneys&amp;#x2019; fees. The Company disputes the allegations and
 filed a motion to dismiss the Complaint on June&amp;#xA0;26, 2015. On
 December&amp;#xA0;30, 2015, the Court dismissed the putative class
 action with prejudice and entered a final judgment in favor of the
 defendants. Plaintiff filed a notice of appeal seeking review of
 the dismissal order and final judgment. The appeal is fully briefed
 and is currently pending before the United States Court of Appeals
 for the Eleventh Circuit.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On August&amp;#xA0;1 and 25, 2014, persons claiming to be Galectin
 shareholders filed putative shareholder derivative complaints in
 the Nevada District Court, seeking recovery on behalf of the
 Company against certain of the Company&amp;#x2019;s directors and
 officers. On September&amp;#xA0;10, 2014, the Nevada District Court
 entered an order consolidating the two cases, relieving the
 defendants of any obligation to respond to the initial complaints,
 and providing that defendants may respond to a consolidated
 complaint to be filed by the plaintiffs. On January&amp;#xA0;5, 2015,
 the Nevada District Court granted Defendants&amp;#x2019; motion to
 transfer the consolidated putative derivative litigation to the
 United States District Court for the Northern District of Georgia
 (hereinafter referred to as the &amp;#x201C;Georgia Federal Derivative
 Action.&amp;#x201D;) The plaintiffs filed a consolidated complaint on
 February&amp;#xA0;27, 2015. On April&amp;#xA0;6, 2015, the Company and
 defendants filed motions to dismiss the consolidated complaint.
 Rather than respond to those motions, the plaintiffs sought and
 obtained leave to file an amended complaint. Plaintiffs filed their
 amended complaint (the &amp;#x201C;Complaint&amp;#x201D;) on May&amp;#xA0;26,
 2015. The Complaint alleges that certain of the Company&amp;#x2019;s
 directors and officers (the &amp;#x201C;Derivative Action Individual
 Defendants&amp;#x201D;) breached their fiduciary duties to the
 Company&amp;#x2019;s shareholders by causing or permitting the Company
 to make allegedly false and misleading public statements concerning
 the Company&amp;#x2019;s financial and business prospects. The Complaint
 also alleges that the Derivative Action Individual Defendants
 violated the federal securities laws by allegedly making false or
 misleading statements of material fact in the Company&amp;#x2019;s proxy
 filings, committed waste of corporate assets, were unjustly
 enriched, and that certain defendants breached their fiduciary
 duties through allegedly improper sales of Galectin stock. In
 addition, the Complaint alleges that the Derivative Action
 Individual Defendants and one of the Company&amp;#x2019;s shareholders
 aided and abetted the alleged breaches of fiduciary duties. The
 Complaint seeks unspecified monetary damages on behalf of the
 Company, corporate governance reforms, disgorgement of profits,
 benefits and compensation by the defendants, costs, and attorneys
 &amp;#x2018;and experts&amp;#x2019; fees. The Company and defendants filed
 motions to dismiss the Complaint on July&amp;#xA0;8, 2015. On
 December&amp;#xA0;30, 2015, the United States District Court for the
 Northern District of Georgia dismissed the Georgia Federal
 Derivative Action with prejudice and entered a final judgment in
 favor of the defendants. Plaintiffs filed a notice of appeal
 seeking review of the dismissal order and final judgment. On
 July&amp;#xA0;7, 2016, the United States Court of Appeals for the
 Eleventh Circuit dismissed the appeal as the Plaintiffs failed to
 timely file their appeal brief.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On August&amp;#xA0;29, 2014, another alleged Galectin shareholder filed
 a putative shareholder derivative complaint in state court in Las
 Vegas, Nevada, seeking recovery on behalf of the Company against
 the same Galectin directors and officers who are named as
 defendants in the derivative litigation pending in the Georgia
 Federal Derivative Action. The plaintiff in the Nevada action
 subsequently filed first and second amended complaints. The second
 amended complaint alleges claims for breach of fiduciary duties,
 unjust enrichment, and waste of corporate assets, based on
 allegations that are substantially similar to those asserted in the
 Georgia Federal Derivative Action (except that the Nevada action
 does not allege violations of the federal securities laws and does
 not assert any claim against the Galectin shareholder named as a
 defendant in the Georgia Federal Derivative Action), and seeks
 unspecified monetary damages on behalf of the Company, corporate
 governance reforms, disgorgement of profits, benefits and
 compensation by the defendants, costs, and attorneys&amp;#x2019; and
 experts&amp;#x2019; fees. The Company and defendants filed motions to
 dismiss the second amended complaint on April&amp;#xA0;22, 2015. On
 April&amp;#xA0;29, 2015, the plaintiffs in the Georgia Federal
 Derivative Action (the &amp;#x201C;Intervenor Plaintiffs&amp;#x201D;) filed a
 motion to intervene in the Nevada action which, among other things,
 raised questions regarding the Nevada plaintiff&amp;#x2019;s standing.
 Thereafter, the Nevada plaintiff filed a motion to join additional
 plaintiffs. At a hearing held on June&amp;#xA0;11, 2015, the Nevada
 court: (i)&amp;#xA0;granted the Intervenor Plaintiffs&amp;#x2019; motion to
 intervene; (ii)&amp;#xA0;directed the Intervenor Plaintiffs to file a
 complaint in intervention; (iii)&amp;#xA0;directed the Nevada plaintiff
 to file a motion for leave to file a further amended complaint to
 add additional plaintiffs; (iv)&amp;#xA0;stated that the
 defendants&amp;#x2019; motions to dismiss the second amended complaint
 were denied &amp;#x201C;at this point;&amp;#x201D; (v)&amp;#xA0;ordered the
 Nevada action stayed until December&amp;#xA0;11 , 2015; and
 (vi)&amp;#xA0;directed the parties to submit a status report on
 December&amp;#xA0;11, 2015, updating the court on the progress and
 status of the Georgia Federal Derivative Action. On July&amp;#xA0;9,
 2015, pursuant to the Nevada State Court&amp;#x2019;s instruction, the
 Intervenor Plaintiffs filed a complaint-in-intervention in Nevada
 State Court, asserting similar claims to the ones they alleged in
 the Georgia Federal Derivative Action described above. On
 December&amp;#xA0;11, 2015, further to the Nevada State Court&amp;#x2019;s
 instruction, the parties submitted status reports detailing the
 status of the Georgia Federal Derivative Action. On January&amp;#xA0;5,
 2016, the Nevada State Court held a status conference during which
 the dismissal of the Georgia Federal Derivative Action was
 discussed. Subsequent to that conference, on January&amp;#xA0;19, 2016,
 the defendants filed a motion to dismiss the Nevada State Court
 litigation based on the dismissal of the similar Georgia Federal
 Derivative Action, among other grounds. Defendants&amp;#x2019; motion to
 dismiss was fully briefed to the Nevada court in February 2016. At
 a hearing on March&amp;#xA0;3, 2016, the Nevada State Court granted
 dismissal of the Nevada State Court litigation pending entry of a
 final order of dismissal. The Nevada State Court issued its order
 of dismissal on April&amp;#xA0;1, 2016. Defendants thereafter filed a
 motion requesting that the Nevada State Court correct certain
 language in the dismissal order. In an order dated June&amp;#xA0;10,
 2016, the Nevada State Court denied Defendants&amp;#x2019; motion
 seeking correction of certain language in the dismissal order. On
 June&amp;#xA0;21, 2016, Notice of Entry of the Nevada State
 Court&amp;#x2019;s order dismissing the Nevada State Court litigation
 was docketed.&amp;#xA0;The Nevada plaintiff and Intervenor Plaintiffs
 have filed notices of appeal seeking review of the Nevada State
 Court&amp;#x2019;s dismissal order.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Estimating an amount or range of possible losses resulting from
 litigation proceedings is inherently difficult and requires an
 extensive degree of judgment, particularly where the matters
 involve indeterminate claims for monetary damages, are in the early
 stages of the proceedings, and are subject to appeal. In addition,
 because most legal proceedings are resolved over extended periods
 of time, potential losses are subject to change due to, among other
 things, new developments, changes in legal strategy, the outcome of
 intermediate procedural and substantive rulings and other
 parties&amp;#x2019; settlement posture and their evaluation of the
 strength or weakness of their case against us. For these reasons,
 we are currently unable to predict the ultimate timing or outcome
 of, or reasonably estimate the possible losses or a range of
 possible losses resulting from, the matters described above. Based
 on information currently available, the Company does not believe
 that any reasonably possible losses arising from currently pending
 legal matters will be material to the Company&amp;#x2019;s results of
 operations or financial condition. However, in light of the
 inherent uncertainties involved in such matters, an adverse outcome
 in one or more of these matters could materially and adversely
 affect the Company&amp;#x2019;s financial condition, results of
 operations or cash flows in any particular reporting period.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Other Legal Proceedings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company records accruals for such contingencies to the extent
 that the Company concludes that their occurrence is probable and
 the related damages are estimable. There are no other pending legal
 proceedings except as noted above.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_8D6AA708-4F16-41EF-BE37-CDE8D26356F5_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;3. Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Following is the stock-based compensation expense related to common
 stock options, common stock, restricted common stock and common
 stock warrants:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 June 30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Six&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 June 30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;179&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;226&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;433&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;543&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;223&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;574&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,192&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,191&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;402&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;800&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,625&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,734&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The following table summarizes the stock option activity in the
 Company&amp;#x2019;s equity incentive plans, including non-plan grants
 to Company executives, from December&amp;#xA0;31, 2015
 through&amp;#xA0;June 30, 2016:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Exercise Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,342,325&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;277,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options forfeited/cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(120,187&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, June&amp;#xA0;30, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,499,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.43&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 As of June&amp;#xA0;30, 2016, there was $1,235,000 of unrecognized
 compensation related to 588,929 unvested options, which is expected
 to be recognized over a weighted&amp;#x2013;average period of
 approximately 1.9 years. The weighted-average grant date fair value
 for options granted during the three months ended June&amp;#xA0;30,
 2016 and 2015 was $1.05 and $2.78, respectively. The Company
 granted 277,500 stock options during the three months ended
 June&amp;#xA0;30, 2016, of which 69,375 options vested upon grant with
 the remaining 208,125 options vesting over 3 years. Approximately
 $73,000 of non-cash, stock-based compensation expense was recorded
 during the three months ended March&amp;#xA0;31, 2016 related to the
 options granted during that quarter that were vested upon the grant
 date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The fair value of all other options granted is determined using the
 Black-Scholes option-pricing model. The following weighted average
 assumptions were used:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Six&lt;br /&gt;
 Months&amp;#xA0;Ended&lt;br /&gt;
 June 30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Six&lt;br /&gt;
 Months&amp;#xA0;Ended&lt;br /&gt;
 June 30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.64&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected life of the options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.0&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.0&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility of the underlying stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;104&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The following table summarizes the restricted stock grant activity
 in the Company&amp;#x2019;s equity incentive plans from
 December&amp;#xA0;31, 2015 through&amp;#xA0;June 30, 2016:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;754,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options forfeited/cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, June&amp;#xA0;30, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;754,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On March&amp;#xA0;12, 2015, the Company granted 81,352 shares of
 restricted stock to non-employee directors as a component of their
 compensation. A total of 77,784 shares were issued to seven
 directors representing non-cash compensation cost of $280,000 which
 will be recognized on a straight-line basis from the grant date
 through December&amp;#xA0;15, 2016, when the restricted shares will
 vest in full. A total of 3,568 shares were issued to two directors,
 who were not nominated for reelection, representing non-cash
 compensation cost of $12,845 that will be recognized on a
 straight-line basis from the grant date through December&amp;#xA0;15,
 2016, when the restricted shares will vest in full.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_7509A141-F008-4056-BC80-26817541A98D_1_4">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_7509A141-F008-4056-BC80-26817541A98D_1_3">2016</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_7509A141-F008-4056-BC80-26817541A98D_1_0">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_C4C4CF4A-0BEB-4BD7-97AB-2AED8E28F92C_1_400002">0001133416</dei:EntityCentralIndexKey>
  <us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_29836441-4DFD-4825-9FE3-BFBE1FCB0297_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;9. Galectin Sciences LLC&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In January 2014, we created Galectin Sciences, LLC (the
 &amp;#x201C;LLC&amp;#x201D; or &amp;#x201C;Investee&amp;#x201D;), a collaborative joint
 venture co-owned by SBH Sciences, Inc. (&amp;#x201C;SBH&amp;#x201D;), to
 research and develop small organic molecule inhibitors of
 galectin-3 for oral administration. The LLC was initially
 capitalized with a $400,000 cash investment to fund future research
 and development activities, which was provided by the Company, and
 specific in-process research and development
 (&amp;#x201C;IPR&amp;amp;D&amp;#x201D;) contributed by SBH.&amp;#xA0;The estimated
 fair value of the IPR&amp;amp;D contributed by SBH, on the date of
 contribution, was $400,000.&amp;#xA0;Initially, the Company and SBH had
 a 50% equity ownership interest in the LLC, with neither party
 having control over the LLC.&amp;#xA0;Accordingly, from inception
 through the fourth quarter of 2014, the Company accounted for its
 investment in the LLC using the equity method of
 accounting.&amp;#xA0;Under the equity method of accounting, the
 Company&amp;#x2019;s investment was initially recorded at cost with
 subsequent adjustments to the carrying value to recognize
 additional investments in or distributions from the Investee, as
 well as the Company&amp;#x2019;s share of the Investee&amp;#x2019;s earnings,
 losses and/or changes in capital. The estimated fair value of the
 IPR&amp;amp;D contributed to the LLC was immediately expensed upon
 contribution as there was no alternative future use available at
 the point of contribution.&amp;#xA0;The operating agreement provides
 that if either party does not desire to contribute its equal share
 of funding required after the initial capitalization, then the
 other party, providing all of the funding, will have its ownership
 share increased in proportion to the total amount contributed from
 inception. In the fourth quarter of 2014, after the LLC had
 expended the $400,000 in cash, SBH decided not to contribute its
 share of the funding required. As a result, the Company contributed
 the $73,000 needed for the fourth quarter of 2014 expenses of the
 LLC. As a result, the Company&amp;#x2019;s ownership percentage in the
 LLC was 54.2% at December&amp;#xA0;31, 2014. The Company contributed
 $687,000 for the LLC expenses in 2015 adjusting the Company&amp;#x2019;s
 ownership percentage to 74.7% at December&amp;#xA0;31, 2015. The
 Company also contributed $441,000 for the LLC expenses in the six
 months ended June&amp;#xA0;30, 2016 which adjusted the Company&amp;#x2019;s
 ownership percentage to 80.2% at June&amp;#xA0;30, 2016. The Company
 accounts for the interest in the LLC as a consolidated, less than
 wholly owned subsidiary. Because the LLC&amp;#x2019;s equity is
 immaterial, the value of the non-controlling interest is also
 deemed to be immaterial.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_1_8">-8100000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_C09BD83E-B556-41AE-A468-D83254DCCDB7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;10. Recent Account Pronouncements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In March 2016, the FASB issued ASU No. 2016-09, Compensation -
 Stock Compensation (Topic 718): Improvements to Employee
 Share-Based Payment Accounting. The new standard requires
 recognition of the income tax effects of vested or settled awards
 in the income statement and involves several other aspects of the
 accounting for share-based payment transactions, including the
 income tax consequences, classification of awards as either equity
 or liabilities and classification on the statement of cash flows.
 The new standard will be effective for us on January 1, 2017. This
 standard is not expected to have a material impact on our financial
 position, results of operations or statements of cash flows upon
 adoption.&lt;/p&gt;
 
 
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_4D2A1FCA-8F8C-4201-88A9-576D178447AF_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Dilutive shares which could exist pursuant to the exercise of
 outstanding stock instruments and which were not included in the
 calculation because their affect would have been anti-dilutive are
 as follows:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;June&amp;#xA0;30,&amp;#xA0;2016&lt;br /&gt;
 (shares)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;June&amp;#xA0;30,&amp;#xA0;2015&lt;br /&gt;
 (shares)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Warrants to purchase shares of common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,908,586&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,370,995&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Options to purchase shares of common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,499,638&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,192,325&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Shares of common stock issuable upon conversion of preferred
 stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,522,936&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,527,103&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Unvested shares of restricted common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;337,935&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;337,935&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,269,095&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,428,358&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_6132495C-E691-4103-92FB-B61A795EE0D2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the restricted stock grant activity
 in the Company&amp;#x2019;s equity incentive plans from
 December&amp;#xA0;31, 2015 through&amp;#xA0;June 30, 2016:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;754,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options forfeited/cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, June&amp;#xA0;30, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;754,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_37C6FA08-A4DD-418A-94C4-28C21344CD35_1_1">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD_per_shares" decimals="0" id="id_8252787_02A8D56D-ECA6-4B2B-9D5A-3A3466F94C00_5001_4">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <dei:TradingSymbol contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_C4C4CF4A-0BEB-4BD7-97AB-2AED8E28F92C_1_400000">GALT</dei:TradingSymbol>
  <dei:AmendmentFlag contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_7509A141-F008-4056-BC80-26817541A98D_1_1">false</dei:AmendmentFlag>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_9761DADC-4791-46A5-917E-71A71AD0A512_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Following is the stock-based compensation expense related to common
 stock options, common stock, restricted common stock and common
 stock warrants:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 June 30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Six&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 June 30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;179&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;226&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;433&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;543&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;223&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;574&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,192&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,191&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;402&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;800&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,625&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,734&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="pure" decimals="2" id="id_8252787_37C6FA08-A4DD-418A-94C4-28C21344CD35_1_3">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="pure" decimals="4" id="id_8252787_37C6FA08-A4DD-418A-94C4-28C21344CD35_1_0">0.0170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="shares" decimals="INF" id="id_8252787_7A8CAF4E-98AB-4CC0-919B-A665DF95C604_5001_5">120187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8252787_02A8D56D-ECA6-4B2B-9D5A-3A3466F94C00_5001_5">3.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8252787_02A8D56D-ECA6-4B2B-9D5A-3A3466F94C00_5001_3">1.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="shares" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_3_13">29001000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:BasisOfAccounting contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_72AFD13F-8CF1-45CE-81ED-4CA44F92F6A1_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;1. Basis of Presentation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Galectin Therapeutics Inc. (the &amp;#x201C;Company&amp;#x201D;) is a
 clinical stage biopharmaceutical company that is applying its
 leadership in galectin science and drug development to create new
 therapies for fibrotic disease and cancer. These candidates are
 based on the Company&amp;#x2019;s targeting of galectin proteins which
 are key mediators of biologic and pathologic function. These
 compounds also may have application for drugs to treat other
 diseases and chronic health conditions.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The unaudited condensed consolidated financial statements as
 reported in this Quarterly Report on Form 10-Q reflect all
 adjustments which are, in the opinion of management, necessary to
 present fairly the financial position of the Company as of
 June&amp;#xA0;30, 2016 and the results of its operations for the three
 and six months ended June&amp;#xA0;30, 2016 and 2015 and its cash flows
 for the six months ended June&amp;#xA0;30, 2016 and 2015. All
 adjustments made to the interim financial statements include all
 those of a normal and recurring nature. The Company considers
 events or transactions that occur after the balance sheet date but
 before the financial statements are issued to provide additional
 evidence relative to certain estimates or to identify matters that
 require additional disclosure. Subsequent events have been
 evaluated through the date these financial statements are available
 to be issued. The results for interim periods are not necessarily
 indicative of results which may be expected for any other interim
 period or for the full year. The unaudited condensed consolidated
 financial statements of the Company should be read in conjunction
 with its Annual Report on Form 10-K for the year ended
 December&amp;#xA0;31, 2015.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has operated at a loss since its inception and has had
 no significant revenues. The Company anticipates that losses will
 continue for the foreseeable future. At June&amp;#xA0;30, 2016, the
 Company had $18.0 million of unrestricted cash and cash equivalents
 available to fund future operations. The Company believes that with
 the cash on hand at June&amp;#xA0;30, 2016, there is sufficient cash to
 fund currently planned operations through June&amp;#xA0;30, 2017. The
 Company&amp;#x2019;s ability to fund operations after its current cash
 resources are exhausted depends on its ability to obtain additional
 financing or achieve profitable operations, as to which no
 assurances can be given. Accordingly, based on the forecasts and
 estimates underlying the Company&amp;#x2019;s current operating plan,
 the financial statements do not currently include any adjustments
 that might be necessary if the Company is unable to continue as a
 going concern.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company was founded in July 2000, was incorporated in the State
 of Nevada in January 2001 under the name
 &amp;#x201C;Pro-Pharmaceuticals, Inc.,&amp;#x201D; and changed its name to
 &amp;#x201C;Galectin Therapeutics Inc.&amp;#x201D; on May&amp;#xA0;26, 2011.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BasisOfAccounting>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_C4C4CF4A-0BEB-4BD7-97AB-2AED8E28F92C_1_400003">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentPeriodEndDate contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_7509A141-F008-4056-BC80-26817541A98D_1_2">2016-06-30</dei:DocumentPeriodEndDate>
  <dei:EntityFilerCategory contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_C4C4CF4A-0BEB-4BD7-97AB-2AED8E28F92C_1_400004">Smaller Reporting Company</dei:EntityFilerCategory>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_C0C44E1F-B277-431D-BEFE-4E67BFE98B32_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the stock option activity in the
 Company&amp;#x2019;s equity incentive plans, including non-plan grants
 to Company executives, from December&amp;#xA0;31, 2015
 through&amp;#xA0;June 30, 2016:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Exercise Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,342,325&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;277,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options forfeited/cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(120,187&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, June&amp;#xA0;30, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,499,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.43&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_C4A0C31F-605D-4D7B-9469-8C27F61D3526_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The fair value of all other options granted is determined using the
 Black-Scholes option-pricing model. The following weighted average
 assumptions were used:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Six&lt;br /&gt;
 Months&amp;#xA0;Ended&lt;br /&gt;
 June 30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Six&lt;br /&gt;
 Months&amp;#xA0;Ended&lt;br /&gt;
 June 30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.64&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected life of the options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.0&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.0&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility of the underlying stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;104&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;
 
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_A012CAC3-B69E-4488-A80E-7443DE17CBBE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the common stock warrant activity
 from December&amp;#xA0;31, 2015 through June&amp;#xA0;30, 2016:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Exercise Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,908,586&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.18&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited/cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, June&amp;#xA0;30, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,908,586&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.18&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="shares" decimals="INF" id="id_8252787_7A8CAF4E-98AB-4CC0-919B-A665DF95C604_5001_3">277500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_4809B841-6E78-4E3B-B2A4-2855183A64F3_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;7. Common Stock&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;2014 At Market Issuance of Common Stock&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On March&amp;#xA0;30, 2014, the Company entered into an At Market
 Issuance Sales Agreement (the &amp;#x201C;2014 At Market
 Agreement&amp;#x201D;) with a sales agent under which the Company may
 issue and sell shares of its common stock having an aggregate
 offering price of up to $30.0 million from time to time through the
 sales agent. Sales of the Company&amp;#x2019;s common stock through the
 sales agent, if any, will be made by any method that is deemed an
 &amp;#x201C;at the market&amp;#x201D; offering as defined by the U.S.
 Securities and Exchange Commission. The Company will pay to the
 sales agent a commission rate equal to 3.0% of the gross proceeds
 from the sale of any shares of common stock sold through the sales
 agent under the 2014 At Market Agreement. In the three months ended
 June&amp;#xA0;30, 2016, the Company issued 176,950 share of common
 stock for net proceeds of approximately $257,000 under the 2014 At
 Market Agreement. In three months ended March&amp;#xA0;31, 2015, the
 Company issued 1,279,416 shares of common stock for net proceeds of
 approximately $4,532,000 under the 2014 At Market Agreement.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="shares" decimals="INF" id="id_8252787_7A8CAF4E-98AB-4CC0-919B-A665DF95C604_5001_4">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_3_12">-0.44</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_E452E194-CED0-4C48-B7BF-B5628D566DE9_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;6. Loss Per Share&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Basic net loss per common share is computed by dividing the net
 loss available to common stockholders by the weighted average
 number of common shares outstanding during the period. Diluted net
 loss per common share is computed by dividing the net loss
 available to common stockholders by the weighted average number of
 common shares and other potential common shares then outstanding.
 Potential common shares consist of common shares issuable upon the
 assumed exercise of in-the-money stock options and warrants and
 potential common shares related to the conversion of the preferred
 stock. The computation of diluted net loss per share does not
 assume the issuance of common shares that have an anti-dilutive
 effect on net loss per share.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Dilutive shares which could exist pursuant to the exercise of
 outstanding stock instruments and which were not included in the
 calculation because their affect would have been anti-dilutive are
 as follows:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;June&amp;#xA0;30,&amp;#xA0;2016&lt;br /&gt;
 (shares)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;June&amp;#xA0;30,&amp;#xA0;2015&lt;br /&gt;
 (shares)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Warrants to purchase shares of common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,908,586&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,370,995&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Options to purchase shares of common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,499,638&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,192,325&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Shares of common stock issuable upon conversion of preferred
 stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,522,936&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,527,103&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Unvested shares of restricted common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;337,935&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;337,935&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,269,095&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,428,358&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <dei:EntityRegistrantName contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_C4C4CF4A-0BEB-4BD7-97AB-2AED8E28F92C_1_400001">GALECTIN THERAPEUTICS INC</dei:EntityRegistrantName>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_0CFF23DA-4B51-4833-99A7-C14D3967F2DB_2_2">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_DC444E4A-50CC-4D6E-97FB-BDC58D98AADC_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;5. Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has certain financial assets and liabilities recorded
 at fair value. Fair values determined by Level 1 inputs utilize
 observable data such as quoted prices in active markets. Fair
 values determined by Level 2 inputs utilize data points other than
 quoted prices in active markets that are observable either directly
 or indirectly. Fair values determined by Level 3 inputs utilize
 unobservable data points in which there is little or no market
 data, which require the reporting entity to develop its own
 assumptions. The carrying amounts reflected in the consolidated
 balance sheets for cash equivalents, accounts payable and accrued
 expenses approximate their carrying value due to their short-term
 nature. There were no level 2 or level 3 assets or liabilities at
 June&amp;#xA0;30, 2016 or December&amp;#xA0;31, 2015.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_F8D22100-FA0F-4727-8E0E-4C322700E1F5_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued expenses consist of the following:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;June&amp;#xA0;30,&lt;br /&gt;
 2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;December&amp;#xA0;31,&lt;br /&gt;
 2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;(in thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Legal and accounting fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;191&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;493&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;626&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued research and development costs and other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,952&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,636&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;845&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="pure" decimals="2" id="id_8252787_37C6FA08-A4DD-418A-94C4-28C21344CD35_1_2">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_3_4">-12345000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_3_8">-12319000</us-gaap:NetIncomeLoss>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_3_6">26000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_3_7">26000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_3_11">-12837000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_1_6">-315000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_1_3">3000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_1_10">0</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_3_9">403000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_1_12">257000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_B01A1D88-4B6D-4992-8340-7893D8EB6CF7_3_2">1625000</us-gaap:ShareBasedCompensation>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_3_2">3742000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_1_13">257000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_3_10">115000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_3_1">8603000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_1_14">-7843000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_1_7">2276000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:OperatingExpenses contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_3_3">12345000</us-gaap:OperatingExpenses>
  <galt:AccruedResearchAndDevelopmentCostsAndOther contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F23BA1BE-2674-45E3-A092-ED3C5261579C_1_2">1952000</galt:AccruedResearchAndDevelopmentCostsAndOther>
  <galt:StockWarrantsTextBlock contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" id="id_8252787_3A23C3C3-B0FF-4A20-AEAB-B1FF0AB80060_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;4. Common Stock Warrants&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the common stock warrant activity
 from December&amp;#xA0;31, 2015 through June&amp;#xA0;30, 2016:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Exercise Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,908,586&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.18&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited/cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, June&amp;#xA0;30, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,908,586&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.18&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</galt:StockWarrantsTextBlock>
  <galt:SupplementalDividendsOnConvertiblePreferredStock contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_642D974B-7551-49B6-B781-1BBB7BF26897_1_18">403000</galt:SupplementalDividendsOnConvertiblePreferredStock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0_1324199x1332392" unitRef="shares" decimals="INF" id="id_8252787_D83D432F-D538-4C61-A63E-13EB8C681DAF_5001_4">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0_1324199x1332392" unitRef="shares" decimals="INF" id="id_8252787_D83D432F-D538-4C61-A63E-13EB8C681DAF_5001_2">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0_1324199x1332392" unitRef="shares" decimals="INF" id="id_8252787_D83D432F-D538-4C61-A63E-13EB8C681DAF_5001_3">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0_1328480x1513856" unitRef="iso4217_USD" decimals="0" id="id_8252787_875CF1B6-F1CC-45AC-80E3-7DA46B538A83_1005_2">441000</us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0_1330097x1336129" unitRef="shares" decimals="INF" id="id_8252787_FF57A2D7-6966-499B-9323-10F2338CEBE6_5001_5">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0_1330097x1336129" unitRef="shares" decimals="INF" id="id_8252787_FF57A2D7-6966-499B-9323-10F2338CEBE6_5001_4">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0_1330097x1336129" unitRef="shares" decimals="INF" id="id_8252787_FF57A2D7-6966-499B-9323-10F2338CEBE6_5001_3">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0_1330097x1336129" unitRef="iso4217_USD_per_shares" decimals="0" id="id_8252787_D4E04A5F-AFE3-4BFF-B2D1-E204048F825F_5001_5">0</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0_1330097x1336129" unitRef="iso4217_USD_per_shares" decimals="0" id="id_8252787_D4E04A5F-AFE3-4BFF-B2D1-E204048F825F_5001_3">0</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0_1330097x1336129" unitRef="iso4217_USD_per_shares" decimals="0" id="id_8252787_D4E04A5F-AFE3-4BFF-B2D1-E204048F825F_5001_4">0</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0_1333589x1330141" unitRef="shares" decimals="INF" id="id_8252787_FE55DE2E-83D2-4220-BA95-CE3BBAA7B77D_1001_2">2522936</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0_1333589x1331109" unitRef="shares" decimals="INF" id="id_8252787_FE55DE2E-83D2-4220-BA95-CE3BBAA7B77D_2001_1">3499638</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0_1333589x1332392" unitRef="shares" decimals="INF" id="id_8252787_FE55DE2E-83D2-4220-BA95-CE3BBAA7B77D_3001_3">337935</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0_1333589x1336129" unitRef="shares" decimals="INF" id="id_8252787_FE55DE2E-83D2-4220-BA95-CE3BBAA7B77D_4001_0">8908586</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0_1334666x1328189" unitRef="iso4217_USD" decimals="-3" id="id_8252787_B01A1D88-4B6D-4992-8340-7893D8EB6CF7_1003_1">1192000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1610-Q0007_STD_182_20160630_0_1334666x1332399" unitRef="iso4217_USD" decimals="-3" id="id_8252787_B01A1D88-4B6D-4992-8340-7893D8EB6CF7_2003_0">433000</us-gaap:ShareBasedCompensation>
  <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="eol_PE87402---1610-Q0007_STD_31_20140131_0_1328480x1513856" unitRef="iso4217_USD" decimals="0" id="id_8252787_875CF1B6-F1CC-45AC-80E3-7DA46B538A83_1002_0">400000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
  <us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions contextRef="eol_PE87402---1610-Q0007_STD_365_20141231_0_1328480x1513856" unitRef="pure" decimals="3" id="id_8252787_875CF1B6-F1CC-45AC-80E3-7DA46B538A83_1003_4">0.542</us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions>
  <galt:AccruedResearchAndDevelopmentCostsAndOther contextRef="eol_PE87402---1610-Q0007_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F23BA1BE-2674-45E3-A092-ED3C5261579C_2_2">96000</galt:AccruedResearchAndDevelopmentCostsAndOther>
  <us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates contextRef="eol_PE87402---1610-Q0007_STD_365_20151231_0_1328480x1513856" unitRef="iso4217_USD" decimals="0" id="id_8252787_875CF1B6-F1CC-45AC-80E3-7DA46B538A83_1001_2">687000</us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates>
  <us-gaap:LossContingencyNewClaimsFiledNumber contextRef="eol_PE87402---1610-Q0007_STD_6_20140806_0" unitRef="LegalMatter" decimals="INF" id="id_8252787_15F8F863-FBA9-4E1C-843F-0E49C86C2221_1_0">3</us-gaap:LossContingencyNewClaimsFiledNumber>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE87402---1610-Q0007_STD_90_20150331_0_1327036x1459062" unitRef="shares" decimals="INF" id="id_8252787_9CDF1BA3-D5D2-47DA-96F0-982D0C0C4ABE_1002_2">1279416</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE87402---1610-Q0007_STD_90_20150331_0_1327036x1459062" unitRef="iso4217_USD" decimals="0" id="id_8252787_9CDF1BA3-D5D2-47DA-96F0-982D0C0C4ABE_1002_3">4532000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE87402---1610-Q0007_STD_91_20150630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8252787_0CFF23DA-4B51-4833-99A7-C14D3967F2DB_3_3">2.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE87402---1610-Q0007_STD_91_20150630_0" unitRef="shares" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_2_13">23731000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE87402---1610-Q0007_STD_91_20150630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_2_12">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE87402---1610-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_2_4">-4657000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE87402---1610-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_2_8">-4643000</us-gaap:NetIncomeLoss>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE87402---1610-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_2_6">14000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE87402---1610-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_2_7">14000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE87402---1610-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_2_11">-4931000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE87402---1610-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_2_9">230000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1610-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_B01A1D88-4B6D-4992-8340-7893D8EB6CF7_2_2">800000</us-gaap:ShareBasedCompensation>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE87402---1610-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_2_2">2057000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="eol_PE87402---1610-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_2_10">58000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE87402---1610-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_2_1">2600000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE87402---1610-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_2_3">4657000</us-gaap:OperatingExpenses>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1610-Q0007_STD_91_20150630_0_1334666x1328189" unitRef="iso4217_USD" decimals="-3" id="id_8252787_B01A1D88-4B6D-4992-8340-7893D8EB6CF7_1002_1">574000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1610-Q0007_STD_91_20150630_0_1334666x1332399" unitRef="iso4217_USD" decimals="-3" id="id_8252787_B01A1D88-4B6D-4992-8340-7893D8EB6CF7_2002_0">226000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1610-Q0007_STD_91_20160331_0_1324199x1331109" unitRef="iso4217_USD" decimals="0" id="id_8252787_0CFF23DA-4B51-4833-99A7-C14D3967F2DB_1004_8">73000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8252787_0CFF23DA-4B51-4833-99A7-C14D3967F2DB_1_3">1.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0" unitRef="shares" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_1_13">29023000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0" unitRef="shares" decimals="INF" id="id_8252787_0CFF23DA-4B51-4833-99A7-C14D3967F2DB_1_4">277500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0" unitRef="shares" decimals="INF" id="id_8252787_0CFF23DA-4B51-4833-99A7-C14D3967F2DB_1_5">69375</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_1_12">-0.20</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_1_4">-5531000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_1_8">-5519000</us-gaap:NetIncomeLoss>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_1_6">12000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_1_7">12000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_1_11">-5827000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_1_9">250000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_B01A1D88-4B6D-4992-8340-7893D8EB6CF7_1_2">402000</us-gaap:ShareBasedCompensation>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_1_2">1305000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_1_10">58000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_1_1">4226000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8252787_F3A245F6-527A-47BD-8E50-C190D4131295_1_3">5531000</us-gaap:OperatingExpenses>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0_1324199x1331109" id="id_8252787_0CFF23DA-4B51-4833-99A7-C14D3967F2DB_1001_7">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0_1327036x1459062" unitRef="shares" decimals="INF" id="id_8252787_9CDF1BA3-D5D2-47DA-96F0-982D0C0C4ABE_1003_2">176950</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0_1327036x1459062" unitRef="iso4217_USD" decimals="0" id="id_8252787_9CDF1BA3-D5D2-47DA-96F0-982D0C0C4ABE_1003_3">257000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0_1334666x1328189" unitRef="iso4217_USD" decimals="-3" id="id_8252787_B01A1D88-4B6D-4992-8340-7893D8EB6CF7_1001_1">223000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1610-Q0007_STD_91_20160630_0_1334666x1332399" unitRef="iso4217_USD" decimals="-3" id="id_8252787_B01A1D88-4B6D-4992-8340-7893D8EB6CF7_2001_0">179000</us-gaap:ShareBasedCompensation>
  <us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates contextRef="eol_PE87402---1610-Q0007_STD_92_20141231_0_1328480x1513856" unitRef="iso4217_USD" decimals="0" id="id_8252787_875CF1B6-F1CC-45AC-80E3-7DA46B538A83_1004_2">73000</us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates>
  <context id="eol_PE87402---1610-Q0007_STD_92_20141231_0_1328480x1513856">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">galt:GalectinSciencesLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-10-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_91_20160630_0_1334666x1332399">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_91_20160630_0_1334666x1328189">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_91_20160630_0_1327036x1459062">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:TwoThousandFourteenAtMarketSalesAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_91_20160630_0_1324199x1331109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_91_20160630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_91_20160331_0_1324199x1331109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_91_20150630_0_1334666x1332399">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_91_20150630_0_1334666x1328189">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_91_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_90_20150331_0_1327036x1459062">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:TwoThousandFourteenAtMarketSalesAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_6_20140806_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2014-08-01</startDate>
      <endDate>2014-08-06</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_365_20151231_0_1328480x1513856">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">galt:GalectinSciencesLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_365_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_365_20141231_0_1328480x1513856">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">galt:GalectinSciencesLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_31_20140131_0_1328480x1513856">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">galt:GalectinSciencesLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_182_20160630_0_1334666x1332399">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_182_20160630_0_1334666x1328189">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_182_20160630_0_1333589x1336129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_182_20160630_0_1333589x1332392">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_182_20160630_0_1333589x1331109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_182_20160630_0_1333589x1330141">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_182_20160630_0_1330097x1336129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_182_20160630_0_1328480x1513856">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">galt:GalectinSciencesLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_182_20160630_0_1324199x1332392">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_182_20160630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_181_20150630_0_1334666x1332399">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_181_20150630_0_1334666x1328189">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_181_20150630_0_1333589x1336129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_181_20150630_0_1333589x1332392">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_181_20150630_0_1333589x1331109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_181_20150630_0_1333589x1330141">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_181_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_1_20150312_0_1324199x1332392_1330194x1472563">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">galt:NonEmployeeBoardOfDirectorsTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-03-12</startDate>
      <endDate>2015-03-12</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_1_20150312_0_1324199x1332392_1330194x1394132">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">galt:NonEmployeeBoardOfDirectorsOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-03-12</startDate>
      <endDate>2015-03-12</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_1_20150312_0_1324199x1332392">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-03-12</startDate>
      <endDate>2015-03-12</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20151231_0_1330097x1336129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20151231_0_1330096x1466234">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBOnePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20151231_0_1330096x1439796">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBTwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20151231_0_1330096x1329983">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20151231_0_1328480x1513856">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">galt:GalectinSciencesLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20151231_0_1324199x1332392">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20160630_0_1336123x1454011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">galt:VestingPeriodOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330097x1336129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1466234">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBOnePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1439796">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBTwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20160630_0_1330096x1329983">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20160630_0_1328480x1513856">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">galt:GalectinSciencesLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20160630_0_1324199x1332392">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20160630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20150312_0_1324199x1332392_1330194x1472563">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">galt:NonEmployeeBoardOfDirectorsTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-03-12</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20150312_0_1324199x1332392_1330194x1394132">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">galt:NonEmployeeBoardOfDirectorsOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-03-12</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20140330_0_1327036x1459062">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:TwoThousandFourteenAtMarketSalesAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20160805_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2016-08-05</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20140131_0_1328480x1513856">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">galt:GalectinSciencesLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-01-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1610-Q0007_STD_0_20140131_0_1324491x1345331_1328480x1513856_1331352x1334714">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">galt:GalectinSciencesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">galt:SbhSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-01-31</instant>
    </period>
  </context>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="Director">
    <measure>galt:Director</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="LegalMatter">
    <measure>galt:LegalMatter</measure>
  </unit>
</xbrl>